Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2015-08-18 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
2015年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "江苏四环生物股份有限公司 2015 年半年度报告全文" which translates to "Jiangsu Sihuan Bioengineering Co., Ltd. 2015 Semi-Annual Report Full Text." It contains detailed financial data, management discussion, business analysis, investment information, and other comprehensive disclosures typical of a semi-annual financial report. The document includes actual financial statements, accounting data, profit and loss analysis, cash flow information, and detailed notes on company operations and governance. The length is substantial (15,000 characters), and it is not merely an announcement or a certification. The content matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year, containing substantive financial data and analysis. Therefore, the correct classification is IR with high confidence. H1 2015
2015-08-18 Chinese
独立董事关于关联方资金往来、对外担保情况的专项说明及独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding related party transactions and external guarantees, referencing regulatory guidance (证监发（2003）56号文). It contains no financial statements or comprehensive financial data, but rather an attestation and opinion on specific corporate governance matters. The document length is short (533 characters), and it is not a full report but a standalone statement. This fits the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles or related attestations, excluding full annual reports. H1 2015
2015-08-18 Chinese
2015年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2015 半年度报告摘要' which translates to '2015 Half-Year Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and changes in shareholders. It also includes management discussion and analysis of business conditions and strategic initiatives. The document is about 3966 characters long, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. The content matches the characteristics of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and includes actual financial statements and management commentary. Therefore, the correct classification is IR (Interim / Quarterly Report). H1 2015
2015-08-18 Chinese
关于公司及子公司部分银行账户被冻结的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the freezing of certain bank accounts of the company and its subsidiary due to a court ruling related to a contract dispute. It details the affected accounts, the company's response, and the impact on operations. There is no financial data, no report attached or referenced as being published, and no mention of annual or interim reports, earnings, or other financial statements. The document is a regulatory announcement about a legal and operational issue affecting the company, fitting best under Regulatory Filings (RNS) as it does not fit other specific categories like Legal Proceedings Report (LTR) because it is more about the announcement of account freezes rather than a detailed legal proceeding update.
2015-08-14 Chinese
澄清公告
Regulatory Filings Classification · 95% confidence The document is a clarification announcement by Jiangsu Sihuan Bio Co., Ltd. addressing rumors and media reports related to a non-public stock issuance and asset acquisition. It includes detailed explanations about the relationships between involved companies and shareholders, and clarifies misunderstandings about the transaction and company control. The document is relatively short (2178 characters) and serves as a public clarification rather than a financial report or detailed filing. It does not contain financial statements, audit results, or detailed financial data. It is not an annual or interim report, nor a call transcript or management report. It is an official announcement responding to regulatory inquiries and media reports, fitting best under Regulatory Filings (RNS) as a general regulatory announcement and clarification.
2015-08-12 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a stock trading abnormal fluctuation announcement by Jiangsu Sihuan Bio Co., Ltd. It discusses unusual stock price movements, company investigations, and clarifications about the absence of undisclosed material information. It also references a previous half-year performance forecast and a non-public stock issuance plan. The document is a regulatory announcement about stock price behavior and related company disclosures, not a financial report or earnings release. It does not contain financial statements or detailed financial data, nor is it a report publication announcement. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about stock trading abnormalities and company disclosures.
2015-08-03 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.